Cision PR Newswire

DTC2026 | World’s First Mass Production of Ultrahigh-Mobility Oxide Technology Paves the Way for a New Generation of Displays

SHENZHEN, China, Nov. 20, 2026 /PRNewswire/ -- TCL CSOT became the world's first to achieve mass production of ultrahigh-mobility oxide technology (electron mobility of ~50 cm²...

AGIBOT Launches Australian Cloud Node to Accelerate Market Expansion and Local Robotics Deployment Across Australia and New Zealand

MELBOURNE, Australia and AUCKLAND, New Zealand, Nov. 20, 2026 /PRNewswire/ -- AGIBOT, a global embodied...

World Gym Corporation Reports Q3 2026 Financial Results

Company Surpasses 300 Locations Worldwide Net Profit of NT$177 Million (US$5.61 Million), Up...

China’s Shaanxi Province Seeks Hong Kong Investment to Boost Industry and Technology

Northwestern province highlights energy projects worth more than 700 billion yuan as it strengthens...

Morrison Announces Middle East Expansion with New Office in Abu Dhabi’s ADGM

ABU DHABI, UAE, Nov. 20, 2026 /PRNewswire/ -- Morrison, a leading global infrastructure investment manager...

Triller Downloads Skyrocket Ahead of TikTok Ban

LOS ANGELES, Jan. 14, 2025 /PRNewswire/ -- Triller, a creator-focused social media platform, has jumped more than 100 spots on the Apple App download...

Cognex Strengthens Market Leadership in Industrial Barcode Reading with Two New AI-Powered Products

DataMan 290 and 390 barcode readers, backed by industry-leading customer support, deliver unmatched reliability and ease of use NATICK, Mass., Jan. 14, 2025 /PRNewswire/ --...

RuggON Launches VIKING II: Transforming Fleet Management with Unmatched Technology and Flexibility

Powered by Android 14 and Qualcomm® Snapdragon™ 6490 Octa-Core Processor, Engineered for Demanding Fleet Applications TAIPEI, Jan. 14, 2025 /PRNewswire/ -- RuggON Corporation proudly...

Korea’s Leading Indie Beauty Brand d’Alba, Reaches New Heights Globally with 210% Overseas Sales Surge

SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- Premium vegan beauty brand d'Alba has achieved significant growth in its overseas sales, rising  to approximately KRW...

ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment,...

SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for 'Pemziviptadil...